RT Journal Article
T1 Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL).
A1 Genescà, Eulàlia
A1 Morgades, Mireia
A1 González-Gil, Celia
A1 Fuster-Tormo, Francisco
A1 Haferlach, Claudia
A1 Meggendorfer, Manja
A1 Montesinos, Pau
A1 Barba, Pere
A1 Gil, Cristina
A1 Coll, Rosa
A1 Moreno, María-José
A1 Martínez-Carballeira, Daniel
A1 García-Cadenas, Irene
A1 Vives, Susana
A1 Ribera, Jordi
A1 González-Campos, José
A1 Díaz-Beya, Marina
A1 Mercadal, Santiago
A1 Artola, María-Teresa
A1 Cladera, Antonia
A1 Tormo, Mar
A1 Bermúdez, Arancha
A1 Vall-Llovera, Ferran
A1 Martínez-Sánchez, Pilar
A1 Amigo, María-Luz
A1 Monsalvo, Silvia
A1 Novo, Andrés
A1 Cervera, Marta
A1 García-Guiñon, Antonio
A1 Ciudad, Juana
A1 Cervera, José
A1 Hernández-Rivas, Jesús-María
A1 Granada, Isabel
A1 Haferlach, Torsten
A1 Orfao, Alberto
A1 Solé, Francesc
A1 Ribera, Josep-Maria
K1 Adult T-ALL
K1 Cytogenetics
K1 NGS
K1 Prognosis
K1 Therapy
AB The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. Complex karyotype defined by the presence of ≥3 cytogenetic alterations identified T-ALL patients with poor prognosis in this study. Karyotypes with ≥3 abnormalities accounted for 16 % (22/139) of all evaluable karyotypes, corresponding to the largest poor prognosis cytogenetic subgroup of T-ALL identified so far. Patients carrying karyotypes with ≥3 cytogenetic alterations showed a significantly inferior response to therapy, and a poor outcome in terms of event-free survival (EFS), overall survival (OS) and cumulative incidence of relapse (CIR), independently of other baseline characteristics and the end-induction minimal residual disease (MRD) level. Additional molecular analyses of patients carrying ≥3 cytogenetic alterations showed a unique molecular profile that could contribute to understand the underlying molecular mechanisms of resistance and to evaluate novel targeted therapies (e.g. IL7R directed) with potential impact on outcome of adult T-ALL patients.
YR 2021
FD 2021-06-08
LK http://hdl.handle.net/10668/18008
UL http://hdl.handle.net/10668/18008
LA en
DS RISalud
RD Apr 5, 2025